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Abstract. Recombinant human PH20 hyaluronidase (rHuPH20) is used to facilitate dispersion of
subcutaneously delivered ﬂuids and drugs. This report summarizes rHuPH20 immunogenicity ﬁndings
from clinical trials where rHuPH20 was co-administered with SC human immunoglobulin, trastuzumab,
rituximab, or insulin. Plasma samples were obtained from evaluable subjects participating in ten different
clinical trials as well as from healthy plasma donors. A bridging immunoassay and a modiﬁed
hyaluronidase activity assay were used to determine rHuPH20-reactive antibody titers and neutralizing
antibodies, respectively. rHuPH20-binding antibody populations from selected subjects with positive
titers were afﬁnity-puriﬁed and subjected to further characterization such as cross-reactivity with
endogenous PH20. Among individual trials, the prevalence of pre-existing rHuPH20-reactive antibodies
varied between 3 and 12%, excepting the primary immunodeﬁciency (PID) studies. Incidence of
treatment-induced rHuPH20 antibodies was 2 to 18%, with the highest titers (81,920) observed in PID.
No neutralizing antibodies were observed. Within most trials, the kinetics of antibody responses were
comparable between pre-existing and treatment-induced antibody responses, although responses
classiﬁed as persistent were more common in subjects with pre-existing titers. There was no association
between antibody positivity and either local or systemic adverse events. Pre-existing and treatment-
induced antibody populations were of similar immunoglobulin isotypes and cross-reacted to endogenous
PH20 to similar extents. No cross-reactivity to PH20 paralogs was detected. rHuPH20 induces only
modest immunogenicity which has no association with adverse events. In addition, antibodies puriﬁed
from baseline-positive individuals are qualitatively similar to those puriﬁed from individuals developing
rHuPH20-reactive antibodies following exposure to the enzyme.
KEY WORDS: anti-drug antibodies; clinical trial; immunogenicity; rHuPH20; subcutaneous drug
delivery.
INTRODUCTION
Hyaluronan (HA) is a mega-dalton glycosaminoglycan
which constitutes a component of the extracellular matrix.
Due to its viscosity and high water binding capacity, the HA
viscoelastic gel forms a barrier to ﬂuid ﬂow and molecular
movement through the interstitial collagenous matrix present
in the hypodermis (1). This places a limit on the volume and
composition of ﬂuids and drugs that can be injected into the
subcutaneous (SC) space. To overcome this limitation,
hyaluronidases puriﬁed from bovine or ovine testes have
been employed for decades to facilitate dispersion and
absorption of subcutaneously injected solutions (2), but their
clinical use has generally been limited by impurity proﬁles (1)
and issues of hypersensitivity reactions (see for example (3)).
More recently, the human testicular hyaluronidase (PH20,
encoded by the gene SPAM1) was cloned and described
as a GPI-anchored protein (4) that possesses hyaluroni-
dase activity (5). This discovery allowed the engineering
of a recombinant form of the human PH20 protein
(rHuPH20) lacking the GPI anchor domain (6) which
can be puriﬁed to homogeneity with a speciﬁc activity 50-
to 100-fold greater than commercially available animal-
derived hyaluronidase products.
The suitability of using rHuPH20 to facilitate dispersion
of injected ﬂuids and drugs was demonstrated preclinically in
models employing rodents (1) as well as pigs (7–9). Clinical
trials with rHuPH20 have been undertaken in the areas of
rapid large volume hydration (10,11), rapid insulin and insulin
analog delivery in subjects with diabetes (12–15), and delivery
of large proteins such as immunoglobulins and monoclonal
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antibodies by SC rather than intravenous (IV) injections
(9,16–21). Importantly, the use of SC rHuPH20 in combina-
tion with various drugs has been demonstrated to generate
pharmacokinetic (PK) proﬁles that provide advantageous or
comparable (i.e., noninferior) characteristics when compared
to those obtained by IV injection of drug alone (16–20,22),
and to increase the absorption rate of SC delivered insulin
and its analogs (12,14,15) as well as morphine (23) among
others. These data demonstrate the potential of rHuPH20 to
facilitate the delivery of a variety of drugs in both acute and
chronic clinical settings, either enabling transition to a more
convenient, patient-friendly route of administration (e.g.,
conversion of treatments from IV to SC) or improving the
PK proﬁle of drugs that are typically administered SC (e.g.,
short acting insulin products).
Even though the use of human proteins as therapeutics
can be expected to reduce immunogenicity relative to non-
human proteins, the potential still exists of an antibody
response. In fact, clinical immunogenicity of recombinant
human proteins is frequently reported (24). The clinical
relevance of those immune responses can vary widely and
must be determined on a case-by-case basis through
investigation of the impact of the immune response on
product efﬁcacy and safety. For example, anti-drug anti-
bodies (ADA) may have signiﬁcant impact on efﬁcacy,
through the development of neutralizing antibodies, and/
or drug PK (25). Cross-reactivity of neutralizing antibod-
ies with an endogenous counterpart can also occur, and in
some cases this has been associated with grave clinical
consequences (26). The potential impact of ADA has led
to the development of regulatory guidelines for immuno-
genicity testing and reporting (27,28). Somewhat surpris-
ingly, a number of cases have been reported in which pre-
existing antibodies to biotherapeutics are present in a
certain percentage of the population, prior to any
exposure to the drug in question (29,30). The reason for
these pre-existing antibodies is typically poorly under-
stood, but their presence can complicate the interpretation
of anti-drug antibody testing results obtained after admin-
istration of the drug in question.
Since rHuPH20 has been used clinically to facilitate
dispersion and absorption of several co-administered
biotherapeutic agents, it represents a unique opportunity
to evaluate immunogenicity in multiple patient popula-
tions and dosing regimens. This report summarizes
rHuPH20 immunogenicity ﬁndings from clinical trials
where rHuPH20 was co-administered SC with human
immunoglobulin, trastuzumab, rituximab, and insulin. In
addition, a study was undertaken to determine the
baseline prevalence of rHuPH20-reactive antibodies in
the general population. Finally, antibodies from subjects
who became positive for rHuPH20-reactive antibodies
following exposure to rHuPH20 were characterized along
with pre-existing antibodies from subjects who had never
been treated with hyaluronidase. Results suggest that
rHuPH20 induces only modest immunogenicity, with no
meaningful changes to adverse event proﬁles. In addition,
antibodies puriﬁed from individuals with pre-existing
positive titers have isotypes and binding characteristics to
endogenous PH20 similar to those puriﬁed from individ-
uals developing rHuPH20-reactive antibodies following
exposure to the protein.
MATERIALS AND METHODS
Clinical Trials
The designs of individual clinical trials for which
immunogenicity analysis of rHuPH20 was conducted are
described in detail in Supplemental 1. A summary of all
included trials is provided in Table I.
Sample Collection
Blood samples, anticoagulated with EDTA, were obtain-
ed at the time of clinic visits according to the individual trial
schedules. When relevant, samples were obtained immedi-
ately prior to the next scheduled treatment of rHuPH20 in
order to avoid drug interference effects. Upon centrifugation,
the resulting plasma was stored at approximately −20°C and
transported frozen to the testing laboratory.
Assays for rHuPH20-Reactive and Neutralizing Antibodies
In order to detect antibodies to rHuPH20, an
electrochemiluminescence (ECL)-based bridging immunoas-
say was developed and validated according to recent
regulatory guidelines (27,28) and white papers (31,32). After
an overnight co-incubation of plasma sample diluted 1:5 with
rHuPH20 conjugated to biotin and rHuPH20 conjugated to
Sulfo-TAG (250 ng/mL each; Meso Scale Discovery,
Rockville, MD), the resulting immune complex was captured
onto streptavidin-coated plates and detected in a SECTOR
2400 instrument using ECL Read buffer (all Meso Scale
Discovery). A three-tiered approach was employed consisting
of screening, speciﬁcity testing using unconjugated rHuPH20
as a competitor, and two-fold step-wise titering in negative
base pool plasma diluted 1:5. Statistically based cut points for
screening positivity, speciﬁcity, and titration were established
as recommended in (32). Individual sample titers were
deﬁned as the last dilution that yielded a positive response.
The positive control for this method was a rabbit anti-
rHuPH20 antibody afﬁnity-puriﬁed from a pool of serum
from three rabbits immunized with rHuPH20 in Freund’s
adjuvant. In order to determine assay sensitivity, a range of
positive control concentrations was spiked into human plasma
and evaluated using the bridging immunoassay to determine
the threshold response versus the established screening cut
point. While some of the ECL responses at 50 pg/mL fell
above the assay cut point, all of the responses at 150 pg/mL
were demonstrated to be greater than the cut point, and
hence this conservative value was chosen to represent assay
sensitivity. Taken into consideration the 1:5 dilution of
plasma, the sensitivity of this assay was thus determined to
be ≤750 pg/mL, a threshold that was 660-fold greater than the
recommended 500 ng/mL for screening assays (28).
In the case of the HyQvia study, primary immunodeﬁ-
ciency (PID) subjects were treated with pools of human IgG,
which were shown to contain low levels of rHuPH20-reactive
antibodies. This is a reﬂection of the baseline prevalence of
anti-rHuPH20 in the general population described in
BResults^ section. Consequently, subjects in this study who
were identiﬁed as not being able to produce mature
antibodies due to their underlying immunodeﬁciency
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syndrome (X-linked agammaglobulinemia, severe combined
immunodeﬁciency, or hyper IgM syndrome) nonetheless
presented with rHuPH20-reactive antibody titers ranging
from 10 to 80, which were interpreted as the result of passive
transfer of the antibodies contained in the therapeutic agent.
Accordingly, HyQvia subjects were only considered to have a
positive rHuPH20-reactive antibody response if a sample titer
was ≥160.
An assay for neutralizing antibodies (nAb) against
rHuPH20 was based on the USP assay for hyaluronidase
activity (33). Brieﬂy, plasma samples diluted 1:20 were pre-
incubated with 2 U/mL rHuPH20 for at least an hour and was
then allowed to digest high molecular weight hyaluronan for
30 min. Addition of acidiﬁed serum resulted in turbidity at
640 nm due to the presence of precipitated hyaluronan which
was monitored spectrophotometrically; any neutralizing anti-
body in the plasma sample diminished the capability of
rHuPH20 activity to lower the turbidity. The minimum
required plasma dilution of 1:20 was determined based on
the potential for interference by known plasma components
such as inter-α-inhibitor (34).
For reporting immunogenicity responses, terms such as
antibody prevalence, incidence, pre-existing and treatment-
induced antibodies, kinetics (transient vs. persistent), and
titer increase over baseline (treatment-boosting) were deﬁned
as in (35). In addition, the requirement for an increase of two
or more titering steps in order to consider a baseline-positive
subject treatment-boosted was also deﬁned as in (35). In this
case, since the titering took place in 2-fold steps, that meant
that a 4-fold or higher increase in titer was required for such
classiﬁcation.
Adverse Events Analysis
For trial 160603/902, each reported adverse event in
subjects that developed rHuPH20-reactive antibodies was
graded mild, moderate, or severe, and the number of adverse
events occurring prior to and following the ﬁrst positive titer
were added for these subjects and expressed per time unit to
yield an adverse events rate.
rHuPH20-Reactive Antibody Purification
For further characterization, rHuPH20-reactive antibod-
ies were afﬁnity-puriﬁed from 130 to 250 mL plasma from
four HyQvia subjects who had previously yielded ECL
bridging immunoassay titers in excess of 10,000 and who
had titers of 2560 to 10,240 at the time of providing the
sample used as a source for antibody. As controls, 700–
800 mL obtained by plasmapheresis of four healthy volun-
teers with rHuPH20-reactive antibody titers of 160–640 was
included. For afﬁnity chromatography, Sepharose 4 Fast Flow
resin (GE Healthcare, Pittsburgh, PA) was conjugated with
rHuPH20 and packaged into Vantage chromatography col-
umns (EMD Millipore, Billerica, MA) connected to an
ÄKTA Puriﬁer instrument (GE Life Sciences, Piscataway, NJ).
Each plasma sample was diluted with 4 vol of TBS and loaded
onto a fresh column, and antibodies were eluted with 0.1 M
glycine-HCl buffer, pH 2.5, and immediately neutralized.
Following dialysis against PBS, samples were concentrated to
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Antibody Isotyping
The resulting puriﬁed antibody preparations were
isotyped using a Human/Non-Human Primate isotyping kit
(Meso Scale Discovery), and IgG subclasses were determined
using a Human IgG subclass proﬁle ELISA for IgG1-IgG3
(Life Technologies), and separately using a Human IgG4
ELISA (eBioscience). Within each preparation, the amount
of each isotype/subclass was expressed as a percentage of the
total amount of antibody.
Evaluation of Antibody Cross-Reactivity
Endogenous PH20 was released from human sperm
(Fairfax Cryobank, Fairfax, VA) by PI-PLC (Sigma-Aldrich,
St. Louis, MO) treatment after capacitation with calcium
ionophore A23187 (Sigma-Aldrich). Recombinant human
PH20 was also released by PI-PLC treatment from DG44-
CHO cells stably transfected with a full-length cDNA construct,
and afﬁnity-puriﬁed using Sepharose 4B conjugated to a rabbit
polyclonal anti-rHuPH20 antibody and otherwise as above. The
concentration of human PH20 in both preparations was
determined using a sandwich ECL assay using the rabbit
polyclonal antibody as a capture antibody in ECL High Bind
plates (Meso Scale Discovery) and a Sulfo-TAG conjugate of
the same antibody as a detecting antibody. Plates were read in a
SECTOR 2400 instrument and concentrations determined using
four-parameter logistic regression on ECL signal obtained using
a dilution series of rHuPH20 as a standard.
In order to compare the binding of rHuPH20-reactive
antibodies to rHuPH20 and endogenous full-length human
PH20, plasma samples conﬁrmed positive for rHuPH20-
reactive antibodies were diluted to yield an ECL signal around
5000 units (between 10- and 40-fold ﬁnal dilution) and subjected
to a version of the ECL bridging immunoassay described above
wherein rHuPH20 conjugates were used at 100 ng/mL. In these
experiments, increasing concentrations of unconjugated
rHuPH20, sperm-derived PH20, and CHO-derived full-length
PH20 were included to compete for binding to rHuPH20-
reactive antibodies present in the sample. The resulting ECL
signal/log competitor concentration curves were analyzed by
four-parameter logistic regression where the top and bottom
asymptotes were constrained as the ECL value obtained from
the un-competed sample mean and the negative control mean,
respectively, and the resulting IC50 value was reported.
To determine whether treatment-induced antibodies
from subjects who participated in the HyQvia trial were
capable of cross-reacting to recombinant human hyaluroni-
dase (Hyal)1 and Hyal2, plasma samples from trial 160603/
902 diluted 1:50 were assayed using the ECL bridging
immunoassay described above in the presence of unlabeled
test antigens added as competitors at a single concentration of
10 μg/mL. Insulin glulisine and rHuPH20 were used as a
negative and positive control competitors, respectively.
RESULTS
Baseline Prevalence and Incidence of rHuPH20-Reactive
Antibodies
The baseline prevalence of rHuPH20-reactive antibodies
prior to exposure to the recombinant protein is summarized for
each clinical trial in Table II and varied between 3.3 and 12.1%,
except for the 160603/902 (primary immunodeﬁciency) trial
where the baseline prevalence was only 1/87. This single
antibody-positive subject had previously been exposed to
rHuPH20 in an earlier trial where immunogenicity was not
monitored, and hence the provenance of this titer (pre-existing
or treatment-induced) is not known. In a study of 961 healthy
plasma donors between the ages of 18 and 65, the prevalence of
Table II. Prevalence and Incidence of rHuPH20-Binding Antibodies in All Clinical Trials




(# subjects) Total incidence
117–203 2/46a (4.3%) 1 0 1/40 (2.5%)
117–205 13/117b (11.1%) 3 2 5/113 (4.4%)
117–206 4/120b (3.3%) 2 0 2/116 (1.7%)
117–403 38/456c (8.3%) 21 3 24/335 (7.2%)
HannaH 22/290 (7.6%) 26 10 36/290 (12.4%)
SparkThera 11/185 (5.9%) 2 4 6/185 (3.2%)
SAWYER 13/107d (12.1%) 3 3 6/96 (6.3%)
SABRINA 28/257e (10.9%) 11 6 17/185 (9.2%)
All rHuPH20 trials except 160603/902 131/1578 (8.3%) 69 28 97/1360 (7.1%)
160603/902 1f/87b (1.1%) 14 1 15/83 (18.1%)
Normals 56/961 (5.8%) n/a n/a n/a
Deﬁnitions of prevalence, incidence, treatment-induced, and treatment-boosted as in (35). The italic text signiﬁes the summation of all
preceding lines
a Including 6 subjects where only a baseline sample was available
b Including 4 subjects where only a baseline sample was available
c Including 114 subjects randomized to receive standard continuous subcutaneous insulin infusion treatment, without rHuPH20, for the period
studied; as well as 7 subjects randomized to receive a treatment regimen containing rHuPH20 but where only baseline and early termination
samples were available
d Including 11 subjects where only a baseline sample was available
e Including 65 subjects randomized to the IV arm, as well as 7 subjects where only a baseline sample was available
fNote that this subject had previously participated in a trial of rHuPH20 and human IgG; however, during this previous trial immunogenicity
monitoring was not performed. Hence, whether this subject was positive prior to any treatment with rHuPH20 is not known
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rHuPH20-reactive antibodies was 5.8%, similar to those ob-
served in the various disease populations. There was no
signiﬁcant difference in prevalence among men and women
(34/450 vs. 22/455, Fisher’s exact p=0.13), and no association
between rHuPH20-reactive antibody positivity and age.
The incidence of rHuPH20-reactive antibodies following
rHuPH20 exposure is also shown in Table II and is deﬁned as
the percentage of subjects that were negative at baseline but
who became positive following exposure (Btreatment-induced^)
plus the percentage of subjects that were positive at baseline and
who had a 4-fold or higher increase of titer following exposure
(Btreatment-boosted^), as outlined in (35). In all cases, the
number of treatment-induced subjects was greater than or
similar to the number of treatment-boosted subjects. The overall
incidence varied from 1.7 to 18.1%.
Samples testing positive for rHuPH20-reactive antibod-
ies were assayed for their ability to neutralize rHuPH20
enzyme activity. No instance of neutralizing antibodies was
found in any sample from any of these clinical trials.
Magnitude of rHuPH20-Reactive Antibody Responses
Titers of rHuPH20-reactive antibodies in the indi-
vidual clinical trials are shown in Fig. 1a. When all
studies were combined (excluding the plasma donor
survey study), the median maximum rHuPH20-reactive
antibody titer in subjects with positive titers at baseline
and subjects who became antibody-positive de novo
following exposure to rHuPH20, respectively, was 40
(range 5–10,240) and 40 (range 5–81,920). Generally,
maximum titers of baseline and treatment-induced anti-
bodies within each population were of similar magnitude,
with two exceptions: Trial 117–206 (type II diabetes, co-
administered with insulin) where the maximum titer
increased following exposure, but was still only at a
median of 160, and trial 160603/902 (primary immunode-
ﬁciency, co-administered with human IgG) where the
highest titers in all of the trials were observed in ﬁve
subjects (Fig. 2).
Fig. 1. a Maximum rHuPH20-reactive antibody titers observed prior to rHuPH20 exposure
(BBaseline^) and in subjects ﬁrst testing positive following rHuPH20 exposure (BInduced^).
Observations for individual subjects with median and interquartile range are indicated. b
Maximum fold titer increase in baseline-positive subjects following rHuPH20 exposure.
Individual subject observations are indicated. Subjects with more than a 2-fold titer increase
following rHuPH20 exposure were considered treatment-boosted (threshold indicated by
gray line). Ten baseline-positive subjects that were never positive following rHuPH20
exposure are not included in this ﬁgure
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In the baseline-positive subjects, the fold change follow-
ing exposure (Fig. 1b) did not indicate systematic titer
boosting by rHuPH20, but some subjects (enumerated in
Table II and shown in Fig. 1b above the gray threshold line)
were considered treatment-boosted using the deﬁnition in
(35). When all trials were considered together, treatment-
boosting occurred in 29 of 110 evaluable baseline-positive
subjects, whereas 71 baseline-positive subjects remained
positive but not treatment-boosted, and ten baseline-positive
subjects were not positive at any time following rHuPH20
exposure. The overall median fold titer change from baseline
at post-exposure maximum was 2 (range 0.125–512). The
highest extent of titer boosting was observed in one subject in
trial 160603/902, who had previously been exposed to
rHuPH20 (see above), as well as in one subject in trial 117–
403 who had a baseline titer at 5 and a titer at 12 months of
2560.
While the highest rHuPH20-binding antibody titer re-
sponses were observed in the 160603/902 trial, titers rapidly
peaked and then decreased despite continued exposure to
rHuPH20. Figure 2 depicts the longitudinal time versus titer
proﬁles for ﬁve subjects over the course of the study who had
maximum antibody titers in excess of 5000. The subject
previously exposed to rHuPH20 (panel a) had a rapid anti-
rHuPH20 antibody response, and rHuPH20 exposure in this
subject was stopped out of an abundance of caution for
further evaluation while antibody titers were monitored over
time. All other subjects (panels b–e) completed the rHuPH20
treatment period. Typically, titers peaked after study day 450
and then reverted back down while the subjects continued to
receive rHuPH20 treatments.
Kinetics of rHuPH20-Reactive Antibody Responses
Evaluations of the kinetics of antibody responses were
possible using data sets from six clinical trials where the
period of antibody monitoring exceeded 16 weeks, or
approximately 5 half-lives of IgG, in at least some of the
subjects in the trial (35). The timing of the onset of antibody
positivity (in subjects negative at baseline) and of the ﬁrst sign
of treatment boosting (in subjects positive at baseline) is
summarized in Fig. 3a and is given as study day without
taking the overall duration of the study into account, nor the
frequency of rHuPH20 administration, so comparison be-
tween trials is not particularly informative. However, within
trials, the onset of de novo antibody positivity and of antibody
boosting was comparable, with one exception: the single
baseline-positive subject in 160603/902 (who was previously
exposed to rHuPH20, see above) had a very rapid onset of
titer boosting compared to the timing of antibody positivity
onset in the baseline-negative subjects in this trial. The timing
of antibody titer maxima (Fig. 3b) also displayed a compara-
ble pattern for baseline-positive subjects and for subjects with
treatment-induced antibodies within each trial, except for
trial 160603/902.
Persistence of antibody positivity was determined in all
subjects where the period of antibody monitoring exceeded
16 weeks. As seen in Fig. 4a, the duration of antibody
positivity was generally longer in subjects who tested positive
for antibodies before rHuPH20 exposure, except in the
SABRINA trial where considerable overlap was observed.
When the deﬁnitions for Bpersistent^ antibody responses
were applied according to (35) (see Fig. 4 legend for
deﬁnition), the percent of antibody-positive subjects having
persistent antibodies was always higher in the baseline-
positive population (75 to 100%) than in the treatment-
induced population (0 to 25%) (Fig. 4b).
Lack of Association Between rHuPH20-Reactive Antibodies
and Adverse Events
In order to determine whether any association
between the conversion to antibody positivity and ad-
verse events could be detected, data from trial 160603/902
were analyzed for all subjects who developed antibodies
following rHuPH20 exposure (Table III). Results indicate
that time-adjusted rates of both local and systemic
adverse events classiﬁed as mild, moderate, and severe
were comparable prior to and following ﬁrst positive titer,
with a slight decrease in each adverse event rate
following rHuPH20-antibody positivity. The similarity of
adverse event rates pre- and post-rHuPH20 antibody
positivity also held true when the 15 subjects from trial
160603/902 were analyzed as a subset, or when the ﬁve
subjects with the highest titers from this trial were
considered on their own.
Fig. 2. Individual rHuPH20-binding antibody titers over time in the
ﬁve subjects from trial 160603/902 who had maximum titers in excess
of 5000. The shaded area in each panel indicates the period of
rHuPH20 exposure. The titers of the single subject with a positive
titer (of 160) prior to participating in this study are shown in panel a
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Characterization of rHuPH20-Reactive Antibodies
In order to compare the characteristics of rHuPH20-
reactive antibodies that emerged following treatment with
rHuPH20 (trial 160603/902, panels a–c and e in Fig. 2) and
those present in baseline-positive individuals, rHuPH20 afﬁnity
chromatography was used to purify antibody preparations from
subjects with titers at the time of plasma donation shown in
Fig. 5a. Following puriﬁcation, the lowest antibody concentra-
tion that could be detected using the bridging immunoassay was
highly variable but within similar ranges for the two populations
(Fig. 5b). Isotyping demonstrated that the two types of antibody
preparations contained comparable proportions of IgM, IgG,
and IgA (Fig. 5c), and percentages of individual IgG subclasses
were also similar with the exception of a single elevated IgG4
level in the treatment-induced group (Fig. 5d).
Cross-reactivity of rHuPH20-reactive antibodies to relat-
ed endogenous proteins, i.e., human sperm-derived PH20 and
paralogous human hyaluronidase proteins, was studied be-
cause of the shared sequence homology between rHuPH20
and these other hyaluronidases (100% between rHuPH20
and endogenous PH20 with the exception of the C-terminal
truncation, and between 34 and 42% homology with hyal-
uronidase (Hyal)-1, -2, -3, and -4 (36)). This evaluation was
performed using a modiﬁcation of the bridging immunoassay,
where unlabeled proteins were used to compete in the bridging
reaction. The data indicate that endogenous PH20 yielded
similar results whether treatment-induced and pre-existing
antibody preparations were tested (Fig. 6a), whereas rHuPH20
tended to inhibit bridging reactions with treatment-induced
antibody preparations more efﬁciently than those with pre-
existing antibodies (Fig. 6b). Under these circumstances, the
highest concentration of rHuPH20 tested (2 μg/mL) inhibited
the bridging signal observed with both treatment-induced and
pre-existing antibodies by >99%.
In separate experiments, plasma samples from four
160603/902 subjects with the highest titer of rHuPH20-
binding antibodies (as shown in Fig. 2a–d), as well as two
subjects deemed antibody-negative, were evaluated for cross-
reactivity to other human hyaluronidases (Hyal-1 and Hyal-2)
Fig. 3. a Onset of rHuPH20-reactive antibody boosting (see deﬁnition in legend for
Fig. 1) in subjects testing positive for antibodies prior to treatment with rHuPH20
(BBaseline Boosted^) and in subjects ﬁrst testing positive following rHuPH20
exposure (BInduced^). b Timing of maximum rHuPH20-reactive antibody titers in
subjects testing positive for antibodies prior to treatment with rHuPH20 (BBaseline^)
and subjects ﬁrst testing positive following rHuPH20 exposure (BInduced^). Individual
observations with median and interquartile range are indicated
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Fig. 4. Persistence of rHuPH20-reactive antibodies in subjects testing positive for
antibodies prior to treatment with rHuPH20 (BBaseline^) and subjects ﬁrst testing
positive following rHuPH20 exposure (BInduced^). a Individual observations with
median and interquartile range are indicated. b Percentage of subjects with
BPersistent^ antibodies according to the deﬁnition in (35) (ﬁrst and last antibody-
positive samples, irrespective of any negative samples in between, are separated
by a period of 16 weeks or longer, or ﬁrst antibody-positive sample is obtained less
than 16 weeks before last sample obtained or end of study)
Table III. Summary of Adverse Eventsa in Baxter Trials in Subjects Who Developed Anti-rHuPH20 Antibodies
Adverse events data set Severity
Before ﬁrst positive anti-rHuPH20 titer After ﬁrst positive anti-rHuPH20 titer
Number of events Rateb Number of events Rate
Total adverse events Mild 72 7.14 202 8.73
Moderate 56 5.55 55 2.38
Severe 10 0.99 9 0.39
Total 138 13.69 266 11.50
Systemic adverse events Mild 49 4.86 135 5.84
Moderate 35 3.47 51 2.20
Severe 7 0.69 9 0.39
Total 91 9.02 195 8.43
Local adverse events Mild 23 2.28 67 2.90
Moderate 21 2.08 4 0.17
Severe 3 0.30 0 0.00
Total 47 4.66 71 3.07
aAdverse events excluding infections
bRate=number of adverse events divided by number of years in the respective observation period, which includes 3683 and 8449 total cumulative
subject days (10.08 and 23.13 total cumulative subject years) of observation prior to and following the ﬁrst exposure to rHuPH20, respectively
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as determined by competition by unlabeled protein at
10 μg/mL in the bridging immunoassay. In these studies,
unlabeled rHuPH20 inhibited the bridging reaction between
the biotinylated- and ruthenylated-rHuPH20 by greater than
99% in all samples except for the two negative samples (<23%).
In contrast, the percentage inhibition for recombinant Hyal-1
and Hyal-2 as well as the glulisine negative control was less than
23% for all samples.
DISCUSSION
The recombinant hyaluronidase, rHuPH20, is used to
facilitate SC delivery of protein therapeutics that would
normally require intravenous infusion and can also be used
to intentionally improve the PK proﬁle of drugs that are
usually administered by SC route. It is typically co-infused SC
along with the therapeutic, either using sequential adminis-
tration or using co-formulated drug product. In either case,
rHuPH20 allows the therapeutic agent to permeate more
readily through the SC space and gain access to the central
circulation via either the capillaries, for small molecule
therapeutics, or the lymphatics, for large molecule therapeu-
tics. This report summarizes the clinical immunogenicity
responses to rHuPH20 in several clinical trials, including
rHuPH20 administered in combination with insulin, thera-
peutic antibodies, or human IgG to a total of 1526 subjects
from diverse populations. Overall, exposure to rHuPH20 was
associated with emergence of rHuPH20-reactive antibodies in
3 to 18% of treated individuals, depending on the trial. Of the
83 individuals who were antibody-negative prior to treatment
and developed rHuPH20-binding titers after exposure to the
protein, only three experienced maximum titers in excess of
10,000 using a highly sensitive bridging immunoassay. In
addition, 28 subjects with pre-existing rHuPH20-reactive
antibodies prior to exposure experienced treatment boosting,
as deﬁned by an increase in titer of two titering steps or more
following treatment, and one of these experienced a maxi-
mum titer of 81,920, the highest titer observed following
rHuPH20 exposure in this data set. Importantly, no neutral-
izing antibodies were identiﬁed in any of these trials.
Fig. 5. Puriﬁcation and characterization of rHuPH20-reactive antibodies from PID
subjects with de novo positive antibody titers following exposure to rHuPH20
(treatment-induced, BTI^) as well as from the baseline-positive population with pre-
existing rHuPH20 antibodies (baseline, BBL^). a Plasma titers at the time of antibody
puriﬁcation. b Lowest detectable concentration of puriﬁed rHuPH20-reactive antibod-
ies in the ECL bridging assay. c Isotypes. d IgG subclasses. Observations from
individual antibody preparations from four individuals each are indicated
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The clinical importance of ADA responses can manifest
itself in various ways: neutralizing antibodies can alter drug
efﬁcacy (25) and, in the worst case, can cross-neutralize the
endogenous counterpart (26); both binding and neutralizing
antibodies can have an impact of the PK of the drug (25); and
circulating ADA-drug immune complexes can form with
potential deleterious safety consequences (37). In the case of
rHuPH20, no potential impact on function of endogenous PH20
should be expected since no neutralizing antibodies were
observed. No clinical data are yet available regarding the
potential effect of anti-rHuPH20 antibodies on PK of
rHuPH20 itself; however, the action of rHuPH20 is localized
to the SC space and no evidence of systemic exposure can be
detected at the doses used (17). This might be related to the
rapid elimination of rHuPH20 from the central compartment.
Even when infused IV in human volunteers, rHuPH20 has a
terminal elimination half-life of only 5–6 min (manuscript in
preparation). Finally, with regards to immune complex forma-
tion, whereas IgG can theoretically distribute to the skin and
lymph (38), there was no difference in adverse event rates in
subjects who eventually became positive for rHuPH20-binding
antibodies when periods prior to and following ﬁrst positive titer
were compared.
A consistent ﬁnding through all the trials was the presence
of rHuPH20-binding antibodies in a small percentage of subjects
prior to rHuPH20 exposure. This was conﬁrmed in a separate
survey study of 961 healthy plasma donors where the prevalence
of pre-existing antibodies was determined to be 6%. The basis
for why they are sometimes present remains unknown but may
be related to immune reactivity to endogenous PH20, a GPI-
anchored hyaluronidase normally present on the apical head of
male sperm (4,5). Whatever their provenance, the presence of
pre-existing rHuPH20-reactive antibodies does not appear to be
associated with systematic titer boosting after exposure to
rHuPH20 in the majority of subjects. Importantly, there were
no adverse events associated with anti-rHuPH20 reactivity, with
or without boosting.
The comparison of several clinical trials with unique study
designs, dose levels of rHuPH20, and sampling schedules can be
fraught with difﬁculty, which can limit the conclusions that can be
Fig. 6. Antibody cross-reactivity to endogenous PH20. a Representative example of
results obtained in the ECL bridging competition assay with an individual rHuPH20-
reactive antibody preparation when increasing concentrations of rHuPH20 or PH20
isolated from human sperm were included. b Resulting IC50 values calculated from
individual antibody preparations. Open circles, rHuPH20-reactive antibodies from
PID subjects with de novo positive antibody titers following exposure to rHuPH20.
Closed circles, rHuPH20-reactive antibodies from the baseline-positive population
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drawn. In the current case, the various trials yielded similar
results in terms of the nature of the rHuPH20 immunogenicity
response: First, within trials, pre-existing and treatment-induced
antibody titers were similar, as were their kinetics of onset of
positivity versus onset of boosting as well as time to maximum
titer. Second, if treatment-induced rHuPH20 antibody responses
occurred, they tended to be more transient in nature than for
pre-existing antibodies. The reason for this is currently unknown,
but could possibly be related to the existence of a robust and
long-lasting immune response to PH20 in individuals with pre-
existing antibodies which predisposed towards more durable
boosting. No data exists to date to address this question. Third,
no neutralizing antibodies were observed in any clinical study.
The notable exception to this pattern was the response
observed in the 160603/902 trial, where rHuPH20 was
administered in combination with human IgG in subjects
with primary immunodeﬁciency and induced a durable
rHuPH20-binding antibody response with titers in excess of
5000 in ﬁve subjects. These titers generally diminished despite
continuing treatment, and no neutralizing antibodies were
ever observed; however, the nature of these responses was
different from those observed in other clinical trials with
rHuPH20. The reason for this could possibly be sought in the
design of the trials (e.g., dosing frequency, total dose) or the
co-administered therapeutic, in this case human IgG puriﬁed
and pooled from plasma donors, which could contain low
levels of rHuPH20-reactive antibodies due to the prevalence
of such antibodies in the general population as described
above. This latter notion was conﬁrmed by analysis of
preparations of human IgG which contained approximately
0.01–0.02% of rHuPH20-reactive antibodies (unpublished
observations). Besides these differences, another potential
reason for the differential immunogenicity response to
rHuPH20 in the 160603/902 trial was the subject population.
Primary immunodeﬁciencies constitute a diverse group of
disorders of monogenic or polygenic origin, where the genetic
basis of the disorder in the more frequently diagnosed
disorders such as CVID is frequently unknown (39). Many
of these diseases predispose affected subjects to dysregulated
T-cell tolerance and autoimmunity (40,41), including CVID
(42), which was diagnosed in three of the ﬁve cases in which
the highest rHuPH20-reactive antibody titers were observed.
Beside the possibility that antibodies to rHuPH20 could
attenuate in vivo enzymatic activity and produce a loss of
dispersive effect at the injection site, the other theoretical
concern is whether these antibodies could affect the functional-
ity of endogenous PH20 or closely related enzymes. In vitro
binding of anti-rHuPH20 antibodies to endogenous PH20would
be expected because of the high homology between rHuPH20
and PH20. On the other hand, binding of such antibodies to
PH20 in vivo would be limited by the limited tissue expression
proﬁle of PH20 (adult male reproductive tract) as well as the
blood-testis and blood-epididymal barriers limiting access of
antibodies in systemic circulation to that milieu (43).
In order to address some of these concerns, treatment-
induced rHuPH20-reactive antibodies as well as those from
baseline-positive subjects were afﬁnity-puriﬁed using rHuPH20-
coupled resin and extensively characterized using various
methods such as antibody titer, antibody isotype, and in vitro
cross-reactivity to endogenous human PH20 and related
hyaluronidases. The resulting antibody preparations from
rHuPH20-treated and baseline-positive subjects had similar
isotypes and IgG subclasses, suggesting that the degree to which
immune class switching had taken place was comparable in both
populations. Cross-reactivity analysis demonstrated that both
types of antibody preparations bound to endogenous PH20
in vitro to a similar degree, whereas the treatment-induced
antibodies bound somewhat better to rHuPH20 than did the
pre-existing ones. This indicates that rHuPH20-binding anti-
bodies emerging following treatment, even in the case of the
comparably high titers occasionally observed in the 160603/902
trial, share molecular and immunological characteristics with
those observed in more than 5% in the general population.
With respect to other human hyaluronidases, the risk of
anti-rHuPH20 antibodies binding to them is lower because the
primary structure of rHuPH20 is only distally related (i.e., 34 to
42% homology) to Hyal-1, -2, -3, and -4 (36). In support of this
notion, none of these plasma samples cross-reacted to recombi-
nant Hyal-1 or Hyal-2 when using the modiﬁed bridging
immunoassay. This conclusion is corroborated by results from
a tissue cross-reactivity study using the afﬁnity-puriﬁed anti-
rHuPH20 antibodies to stain different human tissues (unpub-
lished observations); the only speciﬁc immunohistochemical
staining observed was in the seminiferous tubules in the testis.
This expression proﬁle differs from that observed for other
hyaluronidases, which are expressed in many tissues including
lung, liver, skeletal muscle, and kidney (44). If anti-rHuPH20
antibodies cross-reacted with other hyaluronidase family mem-
bers, multiple tissues would have been expected to be positive in
the tissue cross-reactivity study. Thus, the lack of signal in
multiple assay systems indicates that anti-rHuPH20 antibodies
did not cross-react with PH20 paralogs.
These observations serve to alleviate potential concerns
raised by the apparent binding (although not neutralization)
of a treatment-induced antibody to an endogenous protein
involved in aspects of reproduction and are further supported
by published reports in which several attempts were made to
immunize males with PH20 as an immunocontraceptive
approach in animal models. These studies involved rabbits
(45,46), mice (47), and guinea pigs (48), and only the latter
experienced infertility following PH20 immunization with a
crude testicular extract that resulted in autoimmune orchitis
(49). Furthermore, sperm from mice lacking PH20 were able
to fertilize eggs, albeit in a somewhat delayed manner (50).
In conclusion, rHuPH20 is a recombinant human protein that
appears to havemodest immunogenicity and nodeleterious effects
on efﬁcacy or adverse events. In addition, antibodies that bind to
rHuPH20 are present in about one in 20 healthy individuals not
exposed to the protein, and the functional characteristics of pre-
existing and treatment-induced antibodies are similar. Therefore,
rHuPH20 continues to constitute an attractive therapeutic option
for delivering large molecules and ﬂuid volumes via the SC route
as an alternative to IVadministration.
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